Biosearch Life, a biotechnology company focused on providing innovative solutions worldwide with over 20 years of experience in the research, development, manufacture and commercialisation of natural ingredients, has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the commercialisation of two of its probiotic strains, Lactobacillus fermentum CECT5716 LC40® and Lactobacillus coryniformis CECT5711 K8, aimed at boosting the immune system.
Thanks to the approval obtained by ANVISA, companies in the food supplement, pharmaceutical or food business based in Brazil, will be able to market Biosearch Life’s probiotics in Brazil using these two probiotic strains. According to Business Wire, Brazil’s probiotics market is estimated to be valued at 1,495,345 million dollars and is estimated to grow by 7.01% (CAGR) to reach a market size of 2,245,408 million dollars by 2025.
This is L. fermentum CECT5716 LC40®, a patented probiotic strain, isolated from breast milk that has been clinically proven to provide a high level of protection in infants in cases of respiratory infections and L. coryniformis CECT5711 K8, a strain that boosts the immune system in adults and senior citizens. Both strains, K8 and LC40® have been developed with the aim of helping consumers to have innovative products that provide a direct health benefit.
ANVISA, National Health Surveillance Agency, is an autonomous regulatory body of the Brazilian government. It is responsible for the sanitary control of all products and services subject to health surveillance, such as medicines and food, whether national or imported, and is responsible for the approval of these products for subsequent marketing or production in the country.
In the words of José María Roset, CEO of Biosearch Life, “For us it is great news that ANVISA has approved commercialisation of our two strains in Brazil, a market with high potential for the company and from which we can access new clients seeking to provide probiotic solutions to consumers “.
A